This page shows the latest cemiplimab news and features for those working in and with pharma, biotech and healthcare.
The National Institute for Health and Care Excellence (NICE) has recommended Sanofi and Regeneron’s Libtayo (cemiplimab) for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC). ... The multicentre, non-randomised
In March, Sanofi and Regeneron revealed positive data for their PD-1 inhibitor Libtayo (cemiplimab) in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.
The phase 3 trial had been investigating Libtayo (cemiplimab) in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic. ... Specifically, Libtayo (cemiplimab-rwlc) was cleared for use in newly-diagnosed,
Specifically, Libtayo (cemiplimab-rwlc) has been cleared for use in newly-diagnosed, locally-advanced or metastatic NSCLC patients who have high PD-L1 tumour expression and are not candidates for surgery
Oncology sales were also up in Q4 2020, growing 24.6% to 213m – driven primarily by new launches of multiple myeloma treatment Sarclisa (isatuximab) and skin cancer therapy Libtayo (cemiplimab).
Another is Libtayo (cemiplimab), its latecomer checkpoint inhibitor which has however the first drug in the PD-1/PD-L1 class to be approved for cutaneous squamous cell carcinoma (CSCC), a
More from news
Approximately 3 fully matching, plus 26 partially matching documents found.
Regeneron and its long-standing partners Sanofi look set to gain FDA approval for their PD-1 immunotherapy contender, cemiplimab in October, while Bluebird is poised to file its
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...